Validating Baveno VI and Introducing SAPHE-R: A New Non-Invasive Approach to Rule Out Varices in Hepatocellular Carcinoma Patients

Highlight

  • Baveno VI criteria show suboptimal accuracy for ruling out varices in patients with hepatocellular carcinoma (HCC) and compensated advanced chronic liver disease (cACLD).
  • SAPHE-R, a new non-invasive rule incorporating liver stiffness measurement (LSM), ALBI grade, and platelet count, improves varices exclusion with fewer missed cases than Baveno VI.
  • SAPHE-R reduces the need for invasive upper gastrointestinal endoscopy (UGE), sparing approximately 18% of procedures without compromising safety.
  • External validation confirms SAPHE-R’s robustness, offering a reliable clinical tool for variceal risk stratification in HCC.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply